Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Barinthus Biotherapeutics ( (BRNS) ) is now available.
Barinthus Biotherapeutics has announced the promotion of Geoffrey Lynn, M.D., Ph.D., as the new Chief Scientific Officer, succeeding Nadège Pelletier, Ph.D. This leadership change comes as the company advances its innovative immunotherapeutic pipeline, including promising treatments for chronic hepatitis B and celiac disease. Investors in the biotech sector can look forward to Dr. Lynn’s expertise in driving the development of cutting-edge therapies that aim to tackle autoimmune diseases and chronic infections.
Find detailed analytics on BRNS stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue